The hearing in the high voltage Nexavar case by German drug major Bayer against India's first ever compulsory license (CL) to Natco Pharma will begin in Bombay High Court on October 29. In this case, the multinational drug company is challenging the Intellectual Property Appellate Board (IPAB)'s order in March this year in which the IPAB, Chennai had upheld India’s first ever compulsory license (CL) issued to Hyderabad-based generic drug company Natco Pharma for manufacturing and marketing generic copies of Bayer's patented kidney cancer drug Nexavar.